

# Pelvic organ prolapse and uterine preservation: A case control study (POP-UP study)

**Daniel Gagyor**

Univerzita Palackeho v Olomouci Lekarska fakulta

**Vladimir Kalis**

Univerzita Karlova Lekarska fakulta v Plzni

**Martin Smazinka**

Fakultni Nemocnice Plzen

**Zdenek Rusavy**

Univerzita Karlova Lekarska fakulta v Plzni

**Radovan Pilka**

Univerzita Palackeho v Olomouci Lekarska fakulta

**Khaled Ismail** (✉ [Khaled.Ismail@lfp.cuni.cz](mailto:Khaled.Ismail@lfp.cuni.cz))

Charles University <https://orcid.org/0000-0001-9449-0706>

---

## Research article

**Keywords:** Laparoscopic, Sacrocolpopexy, Cervicopexy, Hysteropexy, LSC, LSCH+LSC, TLH+LSC, LSH, POP-Q, mesh, PFDI, PGI-I, compartment

**Posted Date:** June 26th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-35323/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published on February 17th, 2021. See the published version at <https://doi.org/10.1186/s12905-021-01208-5>.

## Abstract

**Background:** Abdominal and laparoscopic sacro-colpopexy (LSC) is the preferred surgical option for the management of a symptomatic apical pelvic organ prolapse (POP). Women who have their uterus, and for whom an LSC is indicated, can have a laparoscopic sacro-hysteropexy (LSH), a laparoscopic supra-cervical hysterectomy and laparoscopic sacro-cervicopexy (LSCH+LSC) or a total laparoscopic hysterectomy and laparoscopic sacro-colpopexy (TLH+LSC). The main aim of this study was to compare clinical and patient reported outcomes of uterine sparing versus concomitant hysterectomy LSC procedures.

**Methods:** A retrospective analysis of clinical, imaging and patient reported outcomes at baseline, 3 and 12 months after LSH (cases) versus either LSCH+LSC or TLH+LSC between January 2015 and January 2019 in a tertiary referral urogynecology center in Pilsen, the Czech Republic.

**Results.** In total, 294 women were included in this analysis (LSH n = 43, LSCH+LSC n = 208 and TLH+LSC n = 43). There were no differences in the rates of perioperative injuries and complications. Operating time and blood loss were higher in the concomitant hysterectomy compared to the uterine sparing group but this was only significant when comparing LSH to TLH+LSC ( $p = 0.048$ ). There were no statistically significant differences in any of the clinical or patient reported outcomes except for a significantly lower anterior compartment failure rate ( $p = 0.017$ ) and higher optimal mesh placement rate at 12 months in women who had concomitant hysterectomy procedures ( $p = 0.006$ ).

**Conclusion.** LSH is associated with shorter operative time and intraoperative blood loss; nevertheless, higher rates of anterior compartment failures and suboptimal mesh placement.

## Background

It is estimated that one in three and one in 10 women are affected by and require a surgical procedure for pelvic organ prolapse (POP) during their lifetime respectively [1]. POP is associated with numerous bothersome clinical symptoms including pelvic discomfort, vaginal bulge, urinary incontinence, urinary tract symptoms, fecal incontinence or sexual dysfunction. These often have a significant negative impact on their quality of life (QOL) or, even, serious life threatening consequences [2–7]. There is no significant correlation between the severity of clinical symptoms and the stage of POP, but there is a correlation between clinical symptoms and location of the underlying defect [8]. Anterior compartment prolapse tends to be associated with urgency symptoms requiring surgical intervention in the majority of cases [9]. While posterior compartment prolapse is more likely to be associated with distal bowel dysfunction [10, 11].

Conservative management of apical prolapse tends to be offered to women who have not completed their family or those deemed to be at high perioperative and postoperative risks, otherwise surgical correction is the mainstay management. Nevertheless, this option is considered one of the most challenging problems in urogynecology [12]. POP with a dominant apical defect can be treated using a number of surgical approaches [12, 13]. However, high level evidence indicates that abdominal and laparoscopic sacro-colpopexy (LSC) result in better anatomical outcome compared to sacrospinous ligament fixation and transvaginal mesh insertion [13]. Women who have their uterus, and for whom a laparoscopic procedure is indicated, have several surgical options to consider; uterine preservation and a laparoscopic sacro-hysteropexy (LSH), a laparoscopic supra-cervical hysterectomy and laparoscopic sacro-cervicopexy (LSCH + LSC) or a total laparoscopic hysterectomy and laparoscopic sacro-colpopexy (TLH + LSC).

The American College of Obstetricians and Gynecologists considers involving and supporting patients in the discussion about uterine preservation in elective surgery as obligatory [14]. Furthermore, there seems increasing tendency for women to explore uterine preserving procedures for their POP surgical management rather than just accept a hysterectomy [15, 16]. Therefore, increasing the availability of options, that do not necessitate a hysterectomy, gives women viable options to individualize their POP management plan. Nonetheless, one of the important determinants of women's choice about uterine preservation or concomitant hysterectomy is the outcome associated with either procedure [17, 18]. However, at present, there is only limited and heterogenous information about comparative anatomical and functional outcomes of the different variants of LSC with no comprehensive analysis based on whether the uterus was spared or removed [19–22].

## Methods

The main aim of the study was to compare the clinical and patient reported outcomes of uterine sparing versus concomitant hysterectomy LSC procedures for a symptomatic apical POP. As a secondary aim we wanted to assess the peri- and postoperative complications associated with these procedures as an indicator of their safety profile.

This is a retrospective case control study undertaken in a tertiary referral urogynecology center in Pilsen, the Czech Republic. All women referred with an intact uterus and a symptomatic apical POP and who were listed for one of the LSC procedures between January 2015 and January 2019 were included in our analysis. For the purpose of this study, women who had an LSH comprised the cases while the controls were women who had LSCH + LSC or TLH + LSC. Local ethics committee approval was granted for the study. All patients included in this study provided written informed consent for the procedure and for the future use of their perioperative and follow-up data. The departmental medical database was used

to gather data on patients' demographics, medical history, history of abdominal and/or gynecological surgery, previous reconstructive POP surgery, obstetric history, urinary or bowel symptoms and POP-Q staging points [23, 24]. We also collected data on hospital length of stay (LOS). Extended LOS was defined as hospitalization longer than the 75th percentile [25]. The impact of the woman's symptoms on her quality of life during the pre- and postoperative periods was assessed using the Pelvic Floor Distress Inventory (PFDI). This is a validated quality-of-life questionnaire consisting of a Urinary Distress Inventory (UDI), Pelvic Organ Prolapse Distress Inventory (POPDI) and a Colorectal-Anal Distress Inventory (CRADI). UDI and POPDI have a score range of 0 (least impact) to 300 (greatest adverse impact) while CRADI has a range of 0 to 400. Hence, an overall summary PFDI score ranging from 0 to 1000 [26]. Perioperative complications were categorized according to the Dindo-Clavien classification [27].

Surgical procedures were performed by one of four experienced urogynecological subspecialists. The surgical technique, sutures and mesh materials used were identical for all LSC variants and were similar to the previously published technique [28, 29].

In the research unit, postoperative follow-up appointments are routinely arranged at 3 and 12 months for assessment of the impact of surgery on the woman's clinical symptoms, evaluation of any postoperative complications and clinical examination including a POP-Q measurement. In addition to the PFDI, their overall satisfaction with the surgical procedure is routinely evaluated by means of a 7-point Patient Global Impression of Improvement (PGI-I) scale ranging from "Very much worse" (PGI-I = 7) to "Very much better" (PGI-I = 1) [30]. Any identified mesh related complications are reported using the current standardized international classification [31]. A 3D/4D transperineal ultrasound scans is also routinely performed at both follow-up appointments to assess the bladder neck and mesh positions. The ultrasound protocol has been previously published and is derived from the standardized assessment protocol suggested by Dietz et al [28, 29, 32]. Mesh placement is assessed based on a set of composite parameters including: distance of the lowest margin of the anterior mesh strand from the bladder neck < 20 mm [28, 29]; shape of the mesh; absence of folding; and a vertical mesh descent on Valsalva  $\leq$  20 mm.

For the purpose of this study, anatomical apical compartment failure was defined as a postoperative POP-Q point C  $\geq$  -TVL/2 cm. Points Ba and Bp  $\geq$  -1 cm were considered failure in the anterior and posterior compartment respectively. Subjective success of the procedure was defined as a PGI-I < 3. Statistical analysis was performed using IBM SPSS Statistics software version 22 (Armonk, NY: IBM Corp.). A  $p < 0.05$  was considered statistically significant.

In addition to the case control comparisons, we undertook a sub-analysis by type of procedure undertaken.

## Results

A total of 421 LSC procedures were performed during the study period. Of these, 124 (29.5%) procedures were performed on women who previously had a hysterectomy and hence excluded from this study. A further 3 patients (0.7%) were not included because they had their procedure performed through a laparotomy. The remaining 294 (70.0%) women who have had one of the LSC variants for apical POP management were all included in our analysis. Of these, 43 women (14.6%) had LSH, 208 (70.8%) had LSCH + LSC and the remaining 43 women (14.6%) had a TLH + LSC (Fig. 1).

Table 1 and supplementary table 1 summarize participants' characteristics, preoperative POP-Q and PFDI scores grouped by whether the uterus was preserved or not and by type of procedure respectively. There were significant differences between the cohort of women who had LSH compared to LSCH + LSC / TLH + LSC with regards to BMI, age and comorbidities. There was also a significant difference in POP-Q staging based on point Ba between the 2 groups ( $p < 0.0001$ ). There were significant differences in reported urinary hesitancy and constipation between both cohorts ( $p = 0.023$  &  $p = 0.040$  respectively). However, no significant differences were found in other pre-operative POP-Q parameters, reported urinary or anal incontinence, or preoperative PFDI score.

Table 1  
Demographic details of cases and control groups.

| Variable   |                 | Total population<br>N = 294 | Uterine sparing<br>(LSH)<br>N = 43 | Concomitant Hysterectomy<br>(LSCH + LSC & TLH + LSC)<br>N = 251 | p                     |
|--|-----------------|-----------------------------|------------------------------------|---|-----------------------|
| BMI [Median (range)]                                 |                 | 26.4 (17.7–37.2)            | 25.2 (17.7–31.6)                   | 26.6 (19.2–37.2)  | 0.006 <sup>a</sup>    |
| Age [Median (range)]                                 |                 | 63.0 (28–84)                | 49.0 (28–70)                       | 64.0 (37–84)  | < 0.0001 <sup>a</sup> |
| Parity [Median (range)]                              |                 | 2.0 (0–9)                   | 2.0 (1–5)                          | 2.0 (0–9)   | 0.063 <sup>a</sup>    |
| Cardiovascular disease [N (%)]                       |                 | 149 (50.7%)                 | 9 (20.9%)                          | 140 (55.8%)   | < 0.0001 <sup>b</sup> |
| Diabetes mellitus [N (%)]                            |                 | 40 (13.6%)                  | 1 (2.3%)                           | 39 (15.5%)  | 0.020 <sup>b</sup>    |
| Previous DVT or pulmonary embolism [N (%)]           |                 | 39 (13.3%)                  | 3 (7.0%)                           | 36 (14.3%)  | 0.188 <sup>b</sup>    |
| Asthma [N (%)]                                       |                 | 22 (7.5%)                   | 1 (2.3%)                           | 21 (8.4%)   | 0.219 <sup>c</sup>    |
| Previous abdominal surgical history [N (%)]          |                 | 137 (46.6%)                 | 17 (39.5%)                         | 120 (47.8%)   | 0.315 <sup>b</sup>    |
| Previous gynecologic surgery [N (%)]                 |                 | 90 (30.6%)                  | 15 (34.9%)                         | 85 (33.9%)  | 0.896 <sup>b</sup>    |
| Previous POP surgery [N (%)]                         |                 | 6 (2.0%)                    | 2 (4.7%)                           | 4 (1.6%)  | 0.214 <sup>c</sup>    |
| Point C  | POP Q stage     | 19 (6.5%)                   | 5 (11.6%)                          | 14 (5.6%)   | 0.073 <sup>b</sup>    |
|  | POP Q stage II  | 159 (54.1%)                 | 24 (55.8%)                         | 135 (53.8%)   |                       |
|  | POP Q stage III | 78 (26.5%)                  | 11 (25.6%)                         | 67 (26.7%)  |                       |
|  | POP Q stage IV  | 38 (12.9%)                  | 3 (7.0%)                           | 55 (21.9%)  |                       |
| Point Ba   | POP Q stage I   | 3 (1.0%)                    | 1 (2.3%)                           | 2 (0.8%)  | < 0.0001 <sup>b</sup> |
|  | POP Q stage II  | 65 (22.1%)                  | 28 (65.1%)                         | 37 (14.7%)  |                       |
|  | POP Q stage III | 165 (56.1%)                 | 11 (25.6%)                         | 154 (61.4%)   |                       |
|  | POP Q stage IV  | 51 (17.4%)                  | 3 (7.0%)                           | 48 (19.1%)  |                       |
| Point Bp   | POP Q stage I   | 96 (32.7%)                  | 13 (30.2%)                         | 83 (33.1%)  | 0.634 <sup>b</sup>    |
|  | POP Q stage II  | 132 (44.9%)                 | 22 (51.2%)                         | 110 (43.8%)   |                       |
|  | POP Q stage III | 46 (15.6%)                  | 7 (16.3%)                          | 39 (15.5%)  |                       |
|  | POP Q stage IV  | 20 (6.8%)                   | 1 (2.3%)                           | 19 (7.6%)   |                       |
| Stress urinary incontinence [N (%)]                  |                 | 87 (29.6%)                  | 11 (25.6%)                         | 76 (30.3%)  | 0.533 <sup>b</sup>    |
| Urge urinary incontinence [N (%)]                    |                 | 66 (22.4%)                  | 8 (18.6%)                          | 58 (23.1%)  | 0.513 <sup>b</sup>    |
| Hesitancy: a delay in initiating micturition [N (%)] |                 | 136 (46.3%)                 | 13 (30.2%)                         | 123 (49.0%)   | 0.023 <sup>b</sup>    |
| Urinary retention [N (%)]                            |                 | 126 (42.9%)                 | 21 (48.8%)                         | 115 (45.8%)   | 0.714 <sup>b</sup>    |
| Constipation [N (%)]                                 |                 | 62 (21.1%)                  | 4 (9.3%)                           | 58 (23.1%)  | 0.040 <sup>b</sup>    |
| Anal incontinence [N (%)]                            |                 | 102/266 (38.3%)             | 16/41 (39.0%)                      | 86/225 (38.2%)  | 0.923 <sup>b</sup>    |
| Pre-op UDI [median (range)]                          |                 | 51.2 (0-189)                | 52.6 (5.8–164)                     | 51.2 (0-189)  | 0.481 <sup>a</sup>    |
| Pre-op POPDI [median (range)]                        |                 | 68.5 (0-282)                | 58.9 (10.7–152)                    | 69.6 (0-282)  | 0.204 <sup>a</sup>    |
| Pre-op CRADI [median (range)]                        |                 | 35.1 (0-216)                | 34.2 (0-164)                       | 36.4 (0-216)  | 0.963 <sup>a</sup>    |

<sup>a</sup> Mann-Whitney U test; <sup>b</sup> Chi-square Test; <sup>c</sup> Fisher's exact Test

BMI: body mass index, DVT: deep venous thromboembolism

| Variable   | Total population<br>N = 294 | Uterine sparing<br>(LSH)<br>N = 43 | Concomitant Hysterectomy<br>(LSCH + LSC & TLH + LSC)<br>N = 251 | p                  |
|--|-----------------------------|------------------------------------|---|--------------------|
| Pre-op PFDI [median (range)]   | 171.7 (0-600)               | 148.0 (16.5–442)                   | 1712.4 (0-600)  | 0.524 <sup>a</sup> |
| <sup>a</sup> Mann-Whitney U test; <sup>b</sup> Chi-square Test; <sup>c</sup> Fisher's exact Test |                             |                                    |   |                    |
| BMI: body mass index, DVT: deep venous thromboembolism   |                             |                                    |   |                    |

Operative characteristics and postoperative complications are presented in Table 2 and supplementary table 2. Based on the Dindo-Clavien classification, there were no differences in the rates of perioperative injuries and complications. However, operating time and blood loss were higher in the concomitant hysterectomy compared to the uterine sparing group. However, the difference was only significantly longer for operating time in the TLH + LSC versus LSH subgroups ( $p = 0.048$ ). Furthermore, blood loss was significantly higher when comparing TLH + LSC to LSH and TLH + LSC to LSCH + LSC ( $p = 0.001$  and  $< 0.0001$  respectively).

Table 2  
Peri-operative characteristics amongst of cases and controls

| Variable   | Total population<br>N = 294 | Uterine sparing<br>(LSH)<br>N = 43 | Concomitant Hysterectomy<br>(LSCH + LSC & TLH + LSC)<br>N = 251 | p                  |
|--|-----------------------------|------------------------------------|---|--------------------|
| Operating time [min] [Median (range)]                              | 120.5 (60–240)              | 120.0 (70–225)                     | 125.0 (60–240)  | 0.052 <sup>a</sup> |
| Operating time more than 3 hours [N (%)]                           | 16 (5.4%)                   | 2 (4.7%)                           | 14 (5.6%)   | 1.000 <sup>b</sup> |
| Blood loss [ml] [Median (range)]                                   | 150 (50-1400)               | 150 (50-1400)                      | 200 (50–800)  | 0.259 <sup>a</sup> |
| Estimated blood loss more than 300 ml [N (%)]                      | 14 (4.7%)                   | 2 (4.7%)                           | 12 (4.8%)   | 1.000 <sup>b</sup> |
| Perioperative blood transfusion                                    | 2 (0.7%)                    | 1 (2.3%)                           | 1 (0.4%)  | 0.286 <sup>b</sup> |
| Bladder injury [N (%)]   | 10 (3.4%)                   | 2 (4.7%)                           | 8 (3.2%)  | 0.657 <sup>b</sup> |
| Rectal injury [N (%)]  | 0 (0.0%)                    | 0 (0.0%)                           | 0 (0.0%)  | -                  |
| Vaginal injury [N (%)]   | 2 (0.7%)                    | 0 (0.0%)                           | 2 (0.8%)  | 1.000 <sup>b</sup> |
| Early postoperative complications Clavien-Dindo grade 0 [N (%)]    | 281 (95.6%)                 | 41 (95.3%)                         | 240 (95.6%)   | 0,566 <sup>b</sup> |
| Early postoperative complications Clavien-Dindo grade I [N (%)]    | 6 (2.0%)                    | 1 (2.3%)                           | 5 (2.0%)  |                    |
| Early postoperative complications Clavien-Dindo grade II [N (%)]   | 3 (1.0%)                    | 1 (2.3%)                           | 2 (0.8%)  |                    |
| Early postoperative complications Clavien-Dindo grade III [N (%)]  | 4 (1.4%)                    | 0 (0.0%)                           | 4 (1.6%)  |                    |
| Prolonged hospitalization [N (%)]                                  | 6 (2.0%)                    | 2 (4.7%)                           | 4 (1.6%)  | 0.234 <sup>b</sup> |
| <sup>a</sup> Mann-Whitney U test; <sup>b</sup> Fisher's Exact Test |                             |                                    |   |                    |

Table 3 shows anatomical and functional outcomes at 3 and 12 months postoperative. When comparing outcomes in women who had a concomitant hysterectomy at the time of LSC compared to LSH, there were no statistically significant differences in any of the clinical or patient reported outcomes except for a significantly higher anterior compartment failure rate at 12 month follow-up as assessed by POP-Q in women who had a uterine sparing procedure ( $p = 0.017$ ). However, this difference was neither significant when LSH was compared to LSCH + LSC ( $p = 0.105$ ) not to TLH + LSC ( $p = 0.258$ ) (Supplementary table 3). Moreover, concomitant hysterectomy procedures were likely to be associated with absent mesh folding on at 3 and 12 months and optimal composite mesh placement at 12 months as assessed by ultrasonography. These differences reached statistical significance ( $p = 0.004$ ,  $0.021$  and  $0.006$  respectively) (Table 3).

Table 3  
Post-operative follow-up at 3 months (N = 286 (96.3%)) and at 12 months (N = 274 (92.6%)).

|   | 3 month follow-up<br>N = 283 |                                       |   |                    | 12 month follow-up<br>N = 271 |                                       |   |                    |
|---|------------------------------|---------------------------------------|---|--------------------|-------------------------------|---------------------------------------|---|--------------------|
|   | Total<br>N = 283             | Uterine<br>sparing<br>(LSH)<br>N = 41 | Concomitant<br>hysterectomy<br>(LSCH + LSC<br>& TLH + LSC)<br>N = 242 | p                  | Total<br>N = 271              | Uterine<br>sparing<br>(LSH)<br>N = 38 | Concomitant<br>hysterectomy<br>(LSCH + LSC<br>& TLH + LSC)<br>N = 233 | p                  |
| Postoperative complications related to mesh C1-C7 [N/N] (%) | 2/283 (0.7%)                 | 0/41 (0.0%)                           | 2/242 (0.8%)  | 1.000 <sup>b</sup> | 4/271 (1.5%)                  | 1/38 (2.6%)                           | 3/233 (1.3%)  | 0.456 <sup>b</sup> |
| Failure in apical compartment<br>Point C ≥ -TVL/2 [N/N] (%) | 0/283 (0.0%)                 | 0/41 (0.0%)                           | 0/242 (0%)  | -                  | 0/271 (0.0%)                  | 0/38 (0.0%)                           | 0/233 (0%)  | -                  |
| Failure in anterior compartment<br>Point Ba ≥ -1 [N/N] (%)  | 12/283 (4.2%)                | 4/41 (9.8%)                           | 8/242 (3.3%)  | 0.079 <sup>b</sup> | 26/271 (9.6%)                 | 8/38 (21.1%)                          | 18/233 (7.7%)   | 0.017 <sup>b</sup> |
| Failure in posterior compartment<br>Point Bp ≥ -1 [N/N] (%) | 14/283 (4.9%)                | 0/41 (0.0%)                           | 14/242 (5.8%)   | 0.114 <sup>b</sup> | 15/271 (5.5%)                 | 0/38 (0.0%)                           | 15/233 (6.4%)   | 0.140 <sup>b</sup> |
| PGH 1, 2 [N/N] (%)  | 243/283 (85.9%)              | 35/41 (85.4%)                         | 208/242 (86.0%)   | 0.607 <sup>b</sup> | 255/271 (94.1%)               | 33/38 (86.8%)                         | 222/233 (95.3%)   | 0.055 <sup>b</sup> |
| PGH 3 [N/N] (%)   | 28/283 (9.9%)                | 4/41 (9.8%)                           | 24/242 (9.9%)   |                    | 11/271 (4.0%)                 | 3/38 (7.9%)                           | 8/233 (3.4%)  |                    |
| PGH 4 [N/N] (%)   | 8/283 (2.8%)                 | 1/41 (2.4%)                           | 7/242 (2.9%)  |                    | 4/271 (1.5%)                  | 2/38 (5.3%)                           | 2/233 (0.9%)  |                    |
| PGH 5 [N/N] (%)   | 2/283 (0.7%)                 | 1/41 (2.4%)                           | 1/242 (0.4%)  |                    | 1/271 (0.4%)                  | 0/38 (0.0%)                           | 1/233 (0.4%)  |                    |
| PGH 6 [N/N] (%)   | 2/283 (0.7%)                 | 0/41 (0.0%)                           | 2/242 (0.8%)  |                    | 0/271 (0.0%)                  | 0/38 (0.0%)                           | 0/233 (0%)  |                    |
| PGH 7 [N/N] (%)   | 0/286 (0.0%)                 | 0/41 (0.0%)                           | 0/242 (0%)  |                    | 0/271 (0.0%)                  | 0/38 (0.0%)                           | 0/233 (0%)  |                    |
| Δ UUI pre-op – post-op [median (range)]                     | 20.1 (-159-153)              | 17.9 (-54.9-131)                      | 20.1 (-159-153)   | 0.988 <sup>a</sup> | 25.0 (-112-160)               | 17.6 (-99-160)                        | 33.7 (-112-150)   | 0.585 <sup>a</sup> |
| Δ POPDI pre-op – post-op [median (range)]                   | 40.5 (-112-256)              | 35.7 (-56-127)                        | 41.1 (-112-256)   | 0.559 <sup>a</sup> | 39.3 (-74-253)                | 30.4 (-43-135)                        | 48.2 (-189-253)   | 0.502 <sup>a</sup> |
| Δ CRADI pre-op – post-op [median (range)]                   | 7.7 (-189-199)               | 10.0 (-41-129)                        | 7.1 (-189-199)  | 0.338 <sup>a</sup> | 3.6 (-92-170)                 | 10.7 (-38-112)                        | 7.1 (-118-170)  | 0.187 <sup>a</sup> |

<sup>a</sup> Mann-Whitney U test; <sup>b</sup> Fisher's Exact Test; UUI: Urge urinary incontinence; SUI: Stress urinary incontinence.

\* If TVT or bulking agents performed between 3 and 12 months, the woman remained in SUI group.

|   | 3 month follow-up<br>N = 283 |                 |                 |                    | 12 month follow-up<br>N = 271 |                 |                 |                    |
|---|------------------------------|-----------------|-----------------|--------------------|-------------------------------|-----------------|-----------------|--------------------|
| Δ PFDI pre-op – post-op [median (range)]                                  | 46.1 (-342-450)              | 50.7 (-206-373) | 59.5 (-343-450) | 0.889 <sub>a</sub> | 70.4 (-182-460)               | 66.9 (-123-281) | 82.5 (-338-460) | 0.960 <sup>a</sup> |
| De novo SUI [N/N] (%)   | 80/195 (41.0%)               | 13/30 (43.3%)   | 67/165 (40.6%)  | 0.841 <sub>b</sub> | 43/185 (23.2%)                | 12/28 (42.9%)   | 31/157 (19.7%)  | 0.014 <sup>b</sup> |
| De novo SUI [N/N] (%) ≥ weekly*   | 63/195 (32.3%)               | 10/30 (33.3%)   | 53/165 (32.1%)  | 1.000 <sub>b</sub> | 56/186 (30.1%)*               | 11/29 (37.9%)*  | 45/157 (28.7%)  | 0.379 <sup>b</sup> |
| De novo UUI [N/N] (%)   | 18/217(8.3%)                 | 1/33 (3.0%)     | 17/184 (9.2%)   | 0.321 <sub>b</sub> | 13/209 (6.2%)                 | 2/33 (6.1%)     | 11/176 (6.3%)   | 1.000 <sup>b</sup> |
| Improvement of UUI [N/N] (%)  | 47/61 (77.0%)                | 8/8 (100.0%)    | 39/53 (73.6%)   | 0.180 <sub>b</sub> | 51/59 (86.4%)                 | 6/6 (100.0%)    | 45/53 (84.9%)   | 0.348 <sup>b</sup> |
| Improvement of hesitancy: a delay in initiating micturition               | 129/130 (99.2%)              | 13/13 (100.0%)  | 116/117 (99.1%) | 1.000 <sub>b</sub> | 125/126 (99.2%)               | 13/13 (100.0%)  | 111/113 (98.2%) | 1.000 <sup>b</sup> |
| De novo problem of hesitancy: a delay in initiating micturition [N/N] (%) | 2/151 (1.3%)                 | 1/28 (3.6%)     | 1/123 (0.8%)    | 0.337 <sub>b</sub> | 2/146 (1.4%)                  | 1/28 (3.6%)     | 1/118 (0.8%)    | 0.748 <sup>b</sup> |
| Improvement in urinary retention [N/N] (%)                                | 119/131 (90.8%)              | 18/21 (85.7)    | 102/110 (92.7%) | 0.382 <sub>b</sub> | 116/126 (92.1%)               | 18/21 (85.7%)   | 98/105 (93.3%)  | 0.532 <sup>b</sup> |
| De novo urine retention [N/N] (%)   | 5/149 (3.4%)                 | 1/20 (5.0%)     | 4/129 (3.1%)    | 0.519 <sub>b</sub> | 7/145 (4.8%)                  | 1/20 (5.0%)     | 6/125 (4.8%)    | 1.000 <sup>b</sup> |
| Improvement of AI [N/N] (%)   | 67/87 (77.0%)                | 12/13 (92.3%)   | 55/74 (74.3%)   | 0.283 <sub>b</sub> | 61/98 (62.2%)                 | 9/12 (75.0%)    | 52/76 (68.4%)   | 1.000 <sup>b</sup> |
| De novo AI [N/N] (%)  | 24/161 (14.9%)               | 5/26 (19.2%)    | 19/135 (14.1%)  | 0.548 <sub>b</sub> | 22/161 (13.7%)                | 2/25 (8.0%)     | 20/136 (14.7%)  | 1.000 <sup>b</sup> |
| Improvement in constipation [N/N] (%)                                     | 39/59 (66.1%)                | 3/4 (75.0%)     | 36/55 (65.5%)   | 1.000 <sub>b</sub> | 44/60 (73.3%)                 | 3/4 (75.0%)     | 41/56 (73.2%)   | 1.000 <sup>b</sup> |
| De novo constipation [N/N] (%)  | 15/221 (6.8%)                | 3/36 (8.3%)     | 12/185 (6.5%)   | 0.717 <sub>b</sub> | 13/211 (6.2%)                 | 2/35 (5.7%)     | 11/176 (6.3%)   | 1.000 <sup>b</sup> |
| De novo diarrhoea [N/N] (%)   | 1/283 (0.3%)                 | 0/41 (0.0%)     | 1/242 (0.4%)    | 1.000 <sub>b</sub> | 1/271 (0.4%)                  | 0/38 (0.0%)     | 1/233 (0.4%)    | 1.000 <sup>b</sup> |
| De novo painful defecation [N/N] (%)                                      | 2/283 (0.7%)                 | 0/41 (0.0%)     | 2/242 (0.8%)    | 1.000 <sub>b</sub> | 3/271 (1.1%)                  | 0/38 (0.0%)     | 3/233 (1.3%)    | 1.000 <sup>b</sup> |

<sup>a</sup> Mann-Whitney U test; <sup>b</sup> Fisher's Exact Test; UUI: Urge urinary incontinence; SUI: Stress urinary incontinence.

\* If TVT or bulking agents performed between 3 and 12 months, the woman remained in SUI group.

|   | 3 month follow-up<br>N = 283 |              |                 |                    | 12 month follow-up<br>N = 271 |              |                 |                    |
|---|------------------------------|--------------|-----------------|--------------------|-------------------------------|--------------|-----------------|--------------------|
| Distance of the lowest anterior mesh extremity from the bladder neck < 2.0 cm [N/N] (%)   | 260/274(94.9%)               | 39/40(97.5%) | 221/234 (94.4%) | 0.701 <sub>b</sub> | 240/265(90.6%)                | 36/39(92.3%) | 204/226 (90.3%) | 1.000 <sub>b</sub> |
| Regular shape of the mesh upon visualization of the whole mesh [N/N] (%)  | 244/266(91.7%)               | 35/40(87.5%) | 209/226 (92.5%) | 0.345 <sub>b</sub> | 238/265(89.8%)                | 32/39(82.1%) | 206/226 (91.2%) | 0.090 <sub>b</sub> |
| No folding of the mesh [N/N](%)   | 248/268(92.5%)               | 32/40(80.0%) | 216/228 (94.7%) | 0.004 <sub>b</sub> | 245/266(92.1%)                | 32/39(82.1%) | 213/227 (93.8%) | 0.021 <sub>b</sub> |
| No mesh descent on Valsalva 196/226 (86.7%) [N/N] (%)   | 266/268(99.3%)               | 39/40(97.5%) | 227/228 (99.6%) | 0.277 <sub>b</sub> | 252/254(99.2%)                | 36/37(97.3%) | 216/217 (99.5%) | 0.271 <sub>b</sub> |
| Overall evaluation: all criteria for a properly placed mesh fulfilled [N/N] (%)   | 227/266(85.3%)               | 31/40(77.5%) | 196/226 (86.7%) | 0.146 <sub>b</sub> | 214/254(84.3%)                | 25/37(67.6%) | 189/217 (81.7%) | 0.006 <sub>b</sub> |
| <sup>a</sup> Mann-Whitney U test; <sup>b</sup> Fisher's Exact Test; UUI: Urge urinary incontinence; SUI: Stress urinary incontinence. |                              |              |                 |                    |                               |              |                 |                    |
| * If TVT or bulking agents performed between 3 and 12 months, the woman remained in SUI group.  |                              |              |                 |                    |                               |              |                 |                    |

## Discussion

- Summary of findings

To our knowledge, this is the first study comparing outcomes of the different variants of LSC with a particular focus on comparing these outcomes based on whether the uterus was spared or concomitantly removed. Of the total number of women who had an LSC procedure during the study period, 70% of women who presented with a significant apical POP requiring surgery had their uterus in situ. The majority of these women had a concomitant hysterectomy at the time of LSC. Our study demonstrated that LSC procedures with a concomitant total hysterectomy were associated with significantly longer operating time and intra-operative blood loss. In contrast, uterine sparing LSCs were associated with a significantly higher likelihood of a suboptimally placed mesh at 3 and 12 months postoperative and anterior compartment failures at 12 months. Nevertheless, other anatomical and patient reported outcomes were comparable in both groups. On head to head comparison of the different LSC variants there was no significant difference in anterior compartment failure rates. However, this observation should be interpreted with caution due to the small samples in some of the subgroups.

Results in relation to what is known:

Other groups have reported higher rates of anatomical failures in association with LSH [19, 20]. Saliba et al. compared outcomes of 64 LSCH + LSC versus 12 LSH procedures and the anatomical failure, defined as POP stage  $\geq 2$ , was significantly higher in the LSH groups in both any and apical compartments (33.3% vs. 6.2% and 16.7% vs. 0% respectively). The study authors did not provide the actual length of follow-up [20]. Similarly, Gracia and colleagues reported significantly higher apical compartment failures, defined as C stage  $\geq 2$ , when comparing 12 months outcomes after 15 LSH compared to 30 LSCH + LSC (53.2% vs. 10%). Anterior compartment recurrence (Ba stage  $\geq 2$ ) was also more common in their LSH cohort (72.4% vs. 33.3%) [19]. The reported rates of anterior compartment failures concur with our findings of 21.1% vs. 8.8% in our LSH and LSCH + LSC subgroups respectively. Nevertheless, our low rates apical compartment recurrences both in the main and subgroup analyses are in stark contrast to the rates reported in these studies.

When comparing LSH and TLH + LSC, we did not have any apical compartment recurrences at 12 months compared to Pan et al who reported 13.9% and 5.9% recurrence rates for the equivalent procedures in a cohort of 65 and 34 women who had LSH and TLH + LSC respectively, albeit, after an average follow-up of 34 months. While their anterior compartment failure rates were 13.9% versus 11.8% compared to 21.1% versus 5.2% in our study. Moreover, their posterior compartment recurrence rates were 4.6% versus 5.9% while it was 0% and 15.8% in our LSH and TLH + LSC respectively [21]. The identified posterior compartment failure rate in our TLH + LSC was also higher than that reported by Illiano and associates (15.8% compared to 2.4%) [22]. Due to the nature of our study we were not able to explore the reasons behind the aforementioned differences in recurrence rates between our study and previous reports, which could be related to the operative technique, patient selection or duration of follow-up. Another reason for discrepancy in reported outcome rates between various studies is the POP-Q cut-off used to determine failure. Indeed, if we use the Ba > 0 cut-off for cystocele recurrence adopted in other studies [16, 28], our anterior compartment failure rates would have dropped to zero.

We identified a significantly higher likelihood of suboptimal mesh placement in our LSH group, which probably is an indicator of the relative technical difficulty of inserting the mesh in LSH compared to other variants of LSC. The incidence of postoperative mesh-related complications in our study falls within the range of 1.0–2.6%. However, the incidence of mesh erosions were similar in our subgroup analyses unlike the differences reported by other authors [33–35]. It is the technical challenge to achieve proper placement of the anterior mesh in LSH and be able to create a “de novo vaginal apex” that is considered to be a plausible reason for the higher anterior compartment failure in association with LSH and is the driver behind the suggestion of alternative modifications to the standard technique [36].

**Strengths and limitations:**

We appreciate that there are some limitations to our work. First, the retrospective nature of the study has an inherent risk of introducing selection and recall bias into our data. Due to the rigor in our hospital database and the high level of specialism required for the surgical procedures being assessed, it is extremely unlikely we would have missed any procedures or data that was collected. However, the issue of selection bias is more challenging to tackle except within a context of a randomized trial. Indeed, our 2 groups of interest had significant differences in their demographics and associated comorbidities. Second, although we report 12-month follow-up data, in POP surgery, this is considered relatively short. We recognize that the longer the follow-up the higher attrition rate, hence, the current study will form the basis for our LSC database that will enable us to increase our sample size and assess longer term outcomes. Finally, it could be perceived that a report from a single center might limit the external validity of the study. However, the involvement of several independent trained surgeons, in a center accredited by the European Board & College of Obstetrics and Gynaecology (EBCOG) for training and the use of standardized operative technique and validated outcome measures make our findings generalizable. In contrast, the novelty of our study being the first to report on LSC outcomes based on whether the uterus was removed or spared and the use of a comprehensive set of core clinical, imaging and patient reported outcomes are major strengths to our study.

## Conclusion

The majority of women referred with a symptomatic apical POP have their uterus in situ. LSH is associated with shorter operative time and intraoperative blood loss; nevertheless, higher rates of anterior compartment failures and suboptimal mesh placement. LSCH + LSC currently have the best trade-off between operative time, blood loss and recurrence rates at 12 months. The availability of longer-term outcomes for the different LSC variants and the assessment of proposed new modifications to overcome challenges to mesh placement in LSH are essential to give women realistic prospects of making an equitable informed choice.

## Declarations

**Acknowledgement:**

The study was funded by National Sustainability Program I (NPU I) Nr. LO1503 and Charles University Research Fund (Progress Q39). The funders did not have a role in the collection, analysis and interpretation of data and in the writing of the manuscript.

KI is part-funded by project No. CZ.02.1.01/0.0/0.0/16\_019/0000787 “Fighting Infectious Diseases”, awarded by the Ministry of Education, Youth and Sports of the Czech Republic, financed from The European Regional Development Fund. Funders were not involved in the design, analysis or the reporting of this work. Finally, some of the procedures analyzed in this study contributed data to other studies that were designed to answer different research questions [28, 29].

**Availability of data and materials:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests

**Authors' contributions**

DG: Literature search, Data collection, Manuscript writing

VK: Project development, Literature search, Data collection, Manuscript writing

MS: Data collection

ZR: Data collection, Manuscript editing and revision

RP: Project development, Manuscript editing and revision

KMI: Project development, Literature search, Manuscript editing and revision

## References

1. Swift S, Woodman P, O'Boyle A, Kahn M, Valley M, Bland D, et al. Pelvic Organ Support Study (POSST): The distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. *Am J Obstet Gynecol*. 2005;192:795–806. doi:10.1016/j.ajog.2004.10.602.
2. Obinata D, Yamaguchi K, Ito A, Murata Y, Ashikari D, Igarashi T, et al. Lower urinary tract symptoms in female patients with pelvic organ prolapse: Efficacy of pelvic floor reconstruction. *Int J Urol*. 2014;21:301–7. doi:10.1111/iju.12281.
3. Handa VL, Cundiff G, Chang HH, Helzlsouer KJ. Female Sexual Function and Pelvic Floor Disorders. *Obstet Gynecol*. 2008;111:1045–52. doi:10.1097/AOG.0b013e31816bbe85.
4. Slieker-ten Hove MCP, Pool-Goudzwaard AL, Eijkemans MJC, Steegers-Theunissen RPM, Burger CW, Vierhout ME. The prevalence of pelvic organ prolapse symptoms and signs and their relation with bladder and bowel disorders in a general female population. *Int Urogynecol J*. 2009;20:1037–45. doi:10.1007/s00192-009-0902-1.
5. Adjoussou SA, Bohoussou E, Bastide S, Letouzey V, Fatton B, de Tayrac R. Prévalence des troubles fonctionnels et associations anatomofonctionnelles chez les femmes présentant un prolapsus génital. *Progrès en Urol*. 2014;24:511–7. doi:10.1016/j.purol.2013.11.015.
6. Lucassen EA, la Chapelle CF, Krouwel E, Groeneveld M. Renal failure caused by severe pelvic organ prolapse. *BMJ Case Rep*. 2019;12:e229318. doi:10.1136/bcr-2019-229318.
7. Miyagi A, Inaguma Y, Tokoyoda T, Nakajima T, Sezaki R, Matsukawa T. A case of renal dysfunction caused by pelvic organ prolapse. *CEN Case Reports*. 2017;6:125–8. doi:10.1007/s13730-017-0257-2.
8. Wu JM, Vaughan CP, Goode PS, Redden DT, Burgio KL, Richter HE, et al. Prevalence and Trends of Symptomatic Pelvic Floor Disorders in U.S. Women. *Obstet Gynecol*. 2014;123:141–8. doi:10.1097/AOG.0000000000000057.
9. Martan A, Svabík K, Masata J, El-Haddad R, Pavlikova M. [Correlation between stress urinary incontinence or urgency and anterior compartment defect before and after surgical treatment]. *Ces Gynekol*. 2010;75:118–25. <http://www.ncbi.nlm.nih.gov/pubmed/20518265>.
10. Digesu GA, Chaliha C, Salvatore S, Hutchings A, Khullar V. The relationship of vaginal prolapse severity to symptoms and quality of life. *BJOG An Int J Obstet Gynaecol*. 2005;112:971–6. doi:10.1111/j.1471-0528.2005.00568.x.
11. Collins SA, O'Sullivan DM, Lasala CA. Correlation of POP-Q posterior compartment measures with defecatory dysfunction. *Int Urogynecol J*. 2012;23:743–7. doi:10.1007/s00192-011-1643-5.
12. Barber MD, Maher C. Apical prolapse. *Int Urogynecol J*. 2013;24:1815–33. doi:10.1007/s00192-013-2172-1.
13. Maher CM, Feiner B, Baessler K, Glazener CMA. Surgical management of pelvic organ prolapse in women: the updated summary version Cochrane review. *Int Urogynecol J*. 2011;22:1445–57. doi:10.1007/s00192-011-1542-9.
14. Committee Opinion No. 578. *Obstet Gynecol*. 2013;122:1134–8. doi:10.1097/01.AOG.0000437384.88715.03.
15. Meriwether KV, Balk EM, Antosh DD, Olivera CK, Kim-Fine S, Murphy M, et al. Uterine-preserving surgeries for the repair of pelvic organ prolapse: a systematic review with meta-analysis and clinical practice guidelines. *Int Urogynecol J*. 2019;30:505–22. doi:10.1007/s00192-019-03876-2.
16. Gutman RE, Rardin CR, Sokol ER, Matthews C, Park AJ, Iglesia CB, et al. Vaginal and laparoscopic mesh hysteropexy for uterovaginal prolapse: a parallel cohort study. In: *American Journal of Obstetrics and Gynecology*. 2017.
17. Frick AC, Barber MD, Paraiso MFR, Ridgeway B, Jelovsek JE, Walters MD. Attitudes Toward Hysterectomy in Women Undergoing Evaluation for Uterovaginal Prolapse. *Female Pelvic Med Reconstr Surg*. 2013;19:103–9. doi:10.1097/SPV.0b013e31827d8667.
18. Korbly NB, Kassis NC, Good MM, Richardson ML, Book NM, Yip S, et al. Patient preferences for uterine preservation and hysterectomy in women with pelvic organ prolapse. *Am J Obstet Gynecol*. 2013;209:470. doi:10.1016/j.ajog.2013.08.003.
19. Gracia M, Perelló M, Bataller E, Espuña M, Parellada M, Genís D, et al. Comparison between laparoscopic sacral hysteropexy and subtotal hysterectomy plus cervicopexy in pelvic organ prolapse: A pilot study. *Neurourol Urodyn*. 2015;34:654–8. doi:10.1002/nau.22641.
20. Saliba E, Nisolle M, Tchente C, De Landsheere L. Doit-on réaliser systématiquement une hystérectomie subtotale dans le cadre d'une promontofixation coelioscopique ? *Gynécologie Obs Fertil Sénologie*. 2019;47:549–54. doi:10.1016/j.gofs.2019.04.007.
21. Pan K, Cao L, Ryan NA, Wang Y, Xu H. Laparoscopic sacral hysteropexy versus laparoscopic sacrocolpopexy with hysterectomy for pelvic organ prolapse. *Int Urogynecol J*. 2016;27:93–101. doi:10.1007/s00192-015-2775-9.

22. Illiano E, Giannitsas K, Costantini E. Comparison between laparoscopic sacrocolpopexy with hysterectomy and hysteropexy in advanced urogenital prolapse. *Int Urogynecol J*. 2020. doi:10.1007/s00192-020-04260-1.
23. Haylen BT, Maher CF, Barber MD, Camargo S, Dandolu V, Digesu A, et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). *Int Urogynecol J*. 2016;27:165–94. doi:10.1007/s00192-015-2932-1.
24. Haylen BT, Maher CF, Barber MD, Camargo S, Dandolu V, Digesu A, et al. Erratum to: An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). *Int Urogynecol J*. 2016;27:655–84. doi:10.1007/s00192-016-3003-y.
25. Krell RW, Girotti ME, Dimick JB. Extended Length of Stay After Surgery. *JAMA Surg*. 2014;149:815. doi:10.1001/jamasurg.2014.629.
26. Barber MD, Kuchibhatla MN, Pieper CF, Bump RC. Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. *Am J Obstet Gynecol*. 2001;185:1388–95. doi:10.1067/mob.2001.118659.
27. Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. *Ann Surg*. 2004;240:205–13. doi:10.1097/01.sla.0000133083.54934.ae.
28. Smazinka M, Kalis V, Havir M, Havelkova L, Ismail KM, Rusavy Z. Obesity and its long-term impact on sacrocolpopexy key outcomes (OBELISK). *Int Urogynecol J*. 2019. doi:10.1007/s00192-019-04076-8.
29. Kalis V, Smazinka M, Rusavy Z, Blaganje M, Havir M, Havelkova L, et al. Laparoscopic sacrocolpopexy as the mainstay management for significant apical pelvic organ prolapse (LAP) study. *Eur J Obstet Gynecol Reprod Biol*. 2020;244:60–5. doi:10.1016/j.ejogrb.2019.10.049.
30. Srikrishna S, Robinson D, Cardozo L. Validation of the Patient Global Impression of Improvement (PGI-I) for urogenital prolapse. *Int Urogynecol J*. 2010;21:523–8. doi:10.1007/s00192-009-1069-5.
31. Haylen BT, Maher C, Deprest J. IUGA/ICS terminology and classification of complications of prosthesis and graft insertion—re-reading will revalidate. *Am J Obstet Gynecol*. 2013;208:e15. doi:10.1016/j.ajog.2012.08.004.
32. Dietz HP, Haylen BT, Broome J. Ultrasound in the quantification of female pelvic organ prolapse. *Ultrasound Obstet Gynecol*. 2001;18:511–4. doi:10.1046/j.0960-7692.2001.00494.x.
33. Costantini E, Brubaker L, Cervigni M, Matthews CA, O'Reilly BA, Rizk D, et al. Sacrocolpopexy for pelvic organ prolapse: evidence-based review and recommendations. *Eur J Obstet Gynecol Reprod Biol*. 2016;205:60–5. doi:10.1016/j.ejogrb.2016.07.503.
34. Stepanian AA, Miklos JR, Moore RD, Mattox TF. Risk of Mesh Extrusion and Other Mesh-Related Complications After Laparoscopic Sacral Colpopexy with or without Concurrent Laparoscopic-Assisted Vaginal Hysterectomy: Experience of 402 Patients. *J Minim Invasive Gynecol*. 2008;15:188–96. doi:10.1016/j.jmig.2007.11.006.
35. Tan-Kim J, Menefee SA, Lubner KM, Nager CW, Lukacz ES. Prevalence and risk factors for mesh erosion after laparoscopic-assisted sacrocolpopexy. *Int Urogynecol J*. 2011;22:205–12. doi:10.1007/s00192-010-1265-3.
36. Kalis V, Rusavy Z, Ismail KM. Laparoscopic sacrohysteropexy: the Pilsner modification. *Int Urogynecol J*. 2020;31:1277–80. doi:10.1007/s00192-019-04150-1.

## Figures




Figure 1

Flowchart of study participants

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [POPUPstudysupplementarytable1Final.docx](#)
- [POPUPstudysupplementaryTable2Final.docx](#)
- [POPUPstudysupplementaryTable3Final.docx](#)